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Research Article

Human ALPI deficiency causes inflammatory bowel
disease and highlights a key mechanism of
gut homeostasis
Marianna Parlato1,2, Fabienne Charbit-Henrion1,2,3,4, Jie Pan5, Claudio Romano2,6, Rémi DuclauxLoras1,2,3, Marie-Helene Le Du7, Neil Warner5, Paola Francalanci8, Julie Bruneau3,9, Marc Bras10,
Mohammed Zarhrate11, Bernadette Bègue1,2, Nicolas Guegan1,3, Sabine Rakotobe1,2, Nathalie Kapel12,
Paola De Angelis8, Anne M Griffiths5, Karoline Fiedler5 , Eileen Crowley5, Frank Ruemmele1,2,3,4,
Aleixo M Muise5,13,14,†,* & Nadine Cerf-Bensussan1,2,3,†,**

Abstract

Keywords inflammatory bowel diseases; intestinal phosphatase alkaline;
monogenic disease

Herein, we report the first identification of biallelic-inherited
mutations in ALPI as a Mendelian cause of inflammatory bowel
disease in two unrelated patients. ALPI encodes for intestinal phosphatase alkaline, a brush border metalloenzyme that hydrolyses
phosphate from the lipid A moiety of lipopolysaccharides and
thereby drastically reduces Toll-like receptor 4 agonist activity.
Prediction tools and structural modelling indicate that all mutations affect critical residues or inter-subunit interactions, and
heterologous expression in HEK293T cells demonstrated that all
ALPI mutations were loss of function. ALPI mutations impaired
either stability or catalytic activity of ALPI and rendered it unable
to detoxify lipopolysaccharide-dependent signalling. Furthermore,
ALPI expression was reduced in patients’ biopsies, and ALPI activity
was undetectable in ALPI-deficient patient’s stool. Our findings
highlight the crucial role of ALPI in regulating host–microbiota
interactions and restraining host inflammatory responses. These
results indicate that ALPI mutations should be included in screening for monogenic causes of inflammatory bowel diseases and lay
the groundwork for ALPI-based treatments in intestinal inflammatory disorders.
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Introduction
Inflammatory bowel diseases (IBDs) are complex, and severe disorders ascribed to alterations in the dialogue between the microbiota
and the host immune system (Bouma & Strober, 2003; Maloy &
Powrie, 2011). Insights into pathogenesis, first derived from animal
studies, have highlighted how multiple mechanisms cooperate to
build an efficacious and tightly regulated intestinal barrier that
enables hosts to cope with the complex and diverse community of
microbes inhabiting the bowel (Bouma & Strober, 2003; Maloy &
Powrie, 2011). In humans, the common polygenic forms of IBDs
have been thoroughly investigated using genomewide association
studies (GWAS). These studies demonstrated that variants affecting
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expression or function of genes involved in innate defence or cell
homeostasis may predispose to or protect against intestinal
inflammation (Jostins et al, 2012). Recent advances in next-generation sequencing methods have enabled the identification of an
expanding number of monogenic forms of IBDs generally characterized by very early onset and extreme severity (Uhlig, 2013; Uhlig &
Muise, 2017). Genetic dissection of these rare disorders is indispensable to identify as early as possible the best therapeutic option and
to improve long-term outcome and life quality. It also provides
novel insight into the non-redundant mechanisms that are necessary
to maintain mutualistic host–microbiota interactions in the gut.
Sensing of commensal bacteria by Toll-like receptors (TLRs) is
critical to maintain intestinal epithelial homeostasis and to protect
against direct injury (Rakoff-Nahoum et al, 2004), while hyperactive
TLR signalling can foster intestinal inflammation and autoimmunity
in many experimental settings (Asquith et al, 2010). In the gut,
TLR4 is expressed by both epithelial and immune cells and can be
activated by lipopolysaccharides (LPS), a family of complex glycolipids that are major constituents of the outer membrane of Gramnegative bacteria. In order to cope with the huge load of LPS
released in the intestinal lumen by the microbiota and to restrain
TLR4-dependent inflammatory signals, hosts have evolved several
regulatory mechanisms. Animal studies have shown that one crucial
mechanism is intestinal alkaline phosphatase (ALPI), a brush border
metalloenzyme that catalyses phosphate hydrolysis of the lipid
moiety of LPS and thereby drastically reduces LPS pro-inflammatory
activity (Schromm et al, 1998; Goldberg et al, 2008).
Herein, using whole-exome sequencing (WES), we report the identification of ALPI mutations in two unrelated patients displaying severe
intestinal inflammation and autoimmunity. Our data highlight how
LPS detoxification by ALPI plays a crucial role in humans to restrain
inflammatory responses to the microbiota. Moreover, our findings
provide a genetic-based rationale for ALPI oral therapy in IBD.

Results
Clinical description of the patients
Two patients, P1 and P2, from two unrelated kindreds were investigated. P1 was born at term to non-consanguineous parents living in
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Italy. He presented at 2 years of age with severe diarrhoea and
weight loss. Histology showed increased duodenal intraepithelial
lymphocytes with mild villous atrophy (Fig 1A). Since serum IgA
and IgG anti-tissue transglutaminase 2 (anti-TG2) titres were over
100 U/ml and HLA typing revealed DR3-DQ2/DR7-DQ8 haplotypes,
he was diagnosed with coeliac disease (Fig EV1). Gluten-free diet
for 1 year resolved his clinical symptoms and lowered TG2 titres.
He was again referred to the clinic at 3 years of age because of
recurrent abdominal pain, rectal bleeding and severe diarrhoea.
Repeated endoscopic evaluations showed pancolitis with continuous
inflammation and ulcerations of severe intensity from transverse
colon to rectum. Mucosa was normal in the terminal ileum. Histological lesions combined dense lymphoplasmacytic infiltrate,
mucosal ulcerations and erosions, mucin depletion, Paneth cell
metaplasia and diffuse thickening of the muscularis mucosae in all
colonic biopsies. Of note, no epithelioid granulomas were identified.
Immunological workup showed normal serum concentrations of
IgG, IgA, IgE and IgM and negative Epstein–Barr virus and cytomegalovirus serology, but the presence of cytoplasmic anti-neutrophil
cytoplasmic (cANCA) antibodies. Biological evaluation showed
elevated faecal calprotectin (200 lg/g). He was initially treated with
steroids and azathioprine. In view of continued disease activity and
steroid dependence, infliximab was initiated with no significant
improvement. Due to lack of response, he underwent colectomy
with ileorectal anastomosis. No extra-gastrointestinal manifestation
was reported. A first screen using a targeted sequencing of 66 genes
known to be associated with intestinal disorders did not detect any
possibly damaging rare (frequency < 1%) variants in public or inhouse databases (Uhlig et al, 2014).
P2, a boy born to non-consanguineous parents of Jewish
Ashkenazi origin, initially presented at the age of 15.4 years with
non-painful swelling of an ankle and hip. Family history revealed
psoriatic arthritis in a maternal uncle and ulcerative colitis in the
maternal grandmother. P2 was HLA-B27 negative but had antinuclear antibodies (titre 1:320). He was treated with non-steroidal
anti-inflammatory drugs without improvement. Six months later, he
became acutely sick with vomiting and abdominal pain, biological
evidence of severe intestinal inflammation [white cell counts
16 (4–10 × 109/l), neutrophils 12 (2–7.5 × 109/l), platelets 891
(150–400 × 109/l), CRP 127.5 (0–8 mg/l), ESR 93 (1–10 mm/h)],
thickening of small and large bowel wall at ultrasound examination,

B

Figure 1. Colonic inflammation in ALPI-deficient patients.
A, B Haematoxylin–eosin staining of colonic biopsies from P1 (A) and P2 (B). Scale bars: 100 lm (A) and 50 lm (B).
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abnormal distal ileum at barium contrast imaging, endoscopic and
histological evidence of mild inflammation in stomach and duodenum and of more extensive inflammation in the distal intestine with
ulcerations of the ileocaecal valve and of the colon hepatic flexure,
inflamed granulation tissue with a single granuloma in the ascending colon and one ulcer in sigmoid (Fig 1B). Serum IgM was
normal, serum IgG and IgA increased (21.2 and 4.9 g/l, respectively), and anti-TG antibodies were negative. P2 was diagnosed
with ileocolonic Crohn’s disease and was first treated by exclusive
enteral nutrition. Due to iterative clinical symptoms of partial small
bowel obstructions, he received corticosteroids and anti-TNF therapy, and finally underwent ileocaecal resection, which showed
moderate-to-severe chronic active ileitis with transmural chronic
inflammation, fissure-type ulcerations, serosal fibrosis but no
evidence of granulomas. After a few months on metronidazole,
treatment could be discontinued without digestive relapse. His joint
symptoms have resolved post-ileocaecal resection, and he is no
longer on any rheumatological medications.
Identification of heterozygous compound mutations in ALPI
by WES
Whole-exome sequencing was performed on trios including affected
individuals and their unaffected parents. Annotated data were analysed with in-house software. WES of patient 1 (and parents)
resulted in > 144× the mean depth of coverage of the exonic
targeted bases covered by a minimum of 30 independent reads and
identified 101,319 variants. For P2, exome sequencing coverage was
20× or greater for > 85% of the bases targeted and identified
106,869 variants. Polymorphisms reported in public databases with
minor allele frequency (MAF) > 1%, and synonymous variants were
filtered out. Potential pathogenicity of each protein-coding variant
was evaluated using OMIM (Online Mendelian Inheritance in Man),
evolutionary conservation and prediction tools (SIFT, PolyPhen2.2.2, Mutation Taster). Mutations were next ranked by combined
annotation-dependent depletion (CADD) and compared with the
mutation significance cut-off (MSC), a gene-level-specific cut-off for
CADD scores (Itan et al, 2016). This pipeline did not identify any
causal variants in known disease-relevant genes (Appendix Tables
S1 and S2). Instead, it led to the identification of compound
heterozygous mutations in the ALPI gene, encoding intestinal alkaline phosphatase, in both patients (Fig 2A and B, Table 1). Each
variant was confirmed by Sanger sequencing (Figs 2C and EV2)
with the segregation within each family being consistent with autosomal recessive inheritance. ALPI has eleven exons spanning 4.6 kb
(UCSC Genome Browser hg37, chr2:233, 320, 822–233, 325, 455)
and encodes for a 528 amino acid (aa) precursor protein featuring a
signal peptide at its N-terminus (NT; 1–19 aa) and a C-terminal (CT)
phosphatidyl-inositol glycan (GPI) anchor signal (504–528 aa).
Active ALPI consists of two identically processed subunits (each
lacking the first 19 and last 24 aa) bound to the cell surface via a
post-translationally added GPI anchor (Fig 2D). All mutations were
designated as disease causing by the majority of in silico predictions
tools, with three variants resulting in the substitution of residues
highly conserved across species (A97T, A350V and A360; Fig EV2)
and one variant (Q439X) introducing a premature stop codon. Moreover, the combined annotation-dependent depletion (CADD) scores
of each variant were well above the mutation significance cut-off
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(MSC) of 3.13 defined for ALPI (Table 1). All mutations were either
absent or present in only a heterozygous state at a frequency of less
than 0.001% in the Exome Aggregation Consortium (ExAC) database (Table 1; Lek et al, 2016). Overall, in silico analyses suggested
that the four variants identified in the two patients were not irrelevant polymorphisms but rare pathogenic mutations.
Impaired expression of ALPI A97T and Q439X mutants
To assess the impact of the mutations on protein stability of ALPI,
HEK293T cells were stably transduced with lentiviral particles
encoding WT and mutant proteins. In parallel, and in order to define
structure–function correlation, we generated a homology model of
human ALPI based on the crystal structure of human placental alkaline phosphatase (ALPP), which shares 87% identity with ALPI (Le
Du et al, 2001; Appendix Fig S1). We then analysed how mutations
might affect the 3D structure of the ALPI homodimer using ConSurf
server (Ashkenazy et al, 2016).
Immunoblotting (Fig 3A) and cell surface flow cytometry (Fig 3B)
revealed significantly less ALPI protein in HEK293T cells stably transduced with A97T mutant than with the WT construct despite comparable mRNA expression (Fig EV3). Since the highly conserved alanine 97
is located at the b-strand in the dimer interface with each alanine facing
the other (Fig 3C), we posited that substitution by threonine with its
significantly larger, polar projecting side chain might impair protein
dimerization and therefore stability. As expected, given the lack of a
GPI anchoring site at the CT domain, the Q439X truncated protein was
undetectable at the cell surface by flow cytometry (Fig 3B). However, a
weak band with the predicted size of the truncated Q439X mutant was
detected by immunoblot (Fig 3A). Reduced abundance of the corresponding transcript (Fig EV3) suggested nonsense-mediated decay.
Since the 3D model predicts that each CT region is deeply buried at the
interface between the two monomers and engaged in non-covalent
interactions, the lack of CT might also impair proper folding and dimerization of the truncated Q439X mutant and affect protein stability
(Fig 3D, centre). In contrast, A350V and A360V mutants yielded
comparable amount of protein as the WT allele, as assessed by
immunoblotting and flow cytometry (Fig 3A and B).
Impaired function of ALPI A350V and A360V mutants
We next sought to determine the impact of mutations on protein
function by performing in vitro phosphatase activity assays using
para-nitrophenyl phosphate (pNPP) as a chromogenic substrate. In
keeping with their reduced protein expression, A97T and Q439X
mutants showed low or no residual phosphatase activity (Fig 3D). As
indicated above, A350V and A360V mutations did not affect ALPI
expression. Modelling of the ALPP structure further suggested that
neither mutation directly altered the predicted catalytic site (Ser111;
Fig 3E, bottom). However, both modified residues are located on the
same a-helix in the folding core surrounding the catalytic site,
suggesting that the amino acid substitutions may destabilize the overall shape of the phosphatase domain, and thus indirectly affect metal
chelation and/or enzyme activity. In support of this hypothesis, the
enzymatic activity of A350V and A360V mutants was significantly
reduced to 10 and 30% of WT ALPI activity, respectively (Fig 3F).
ALPI has been shown to detoxify LPS molecules by removing a
phosphate group from its lipid A moiety. The resulting
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Figure 2. WES identification of heterozygous compound mutations in ALPI.
A
B
C
D

Variant identification pipeline for WES in P1 and P2 (see also Appendix Tables S1 and S2).
Unrelated familial trees showing affected children in black and healthy individuals in white.
Sanger sequencing of the region corresponding to mutations in ALPI in both families.
Location of ALPI on chromosome 2 and diagrams featuring ALPI gene with its nine exons and ALPI protein with its N-terminal signal peptide, phosphatase domain
and C-terminal recognition signal for the transamidase complex (GPI-anchor attachment site), which removes the GPI signal sequence and replaces it by a preformed
GPI precursor glycolipid. Arrows point to mutations identified in P1 and P2. Numbers indicate amino acid position.
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Table 1. Features of variants identified in P1 and P2.
Position

Prediction

Patient

Exon

Genomic
Chr2
(GRCh37)

1

3

g.233321394G>A

c.289G>A

p.Ala97Thr

0.0004362

9

g.233322984C>T

c.1049C>T

p.Ala350Val

9

g.233323014C>T

c.1079C>T

11

g.233323584C>T

c.1315C>T

2

cDNA
NM_001631.4

Proteins

MAF

CADD
MSC:3.13

Mutation
Taster

PoliPhen-2

SIFT

27.1

Probably
damaging
score: 1.0

Deleterious
score: 0.03

Disease
causing Pvalue: 0.997

No Freq

19.95

Possibly
damaging
score: 0.532

Tolerated
score: 0.35

Disease
causing Pvalue: 0.644

p.Ala360Val

0.0006363

27.8

Probably
damaging
score: 0.990

Tolerated
score: 0.36

Disease
causing Pvalue: 1

p.Gln439X

0.0001295

19.3

–

–

–

MAF, minor allelic frequency based on 60,706 individuals genotyped as part of the Exome Aggregation Consortium (ExAC: http://exac.broadinstitute.org). Variant
predictions are based on PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), SIFT (http://sift.jcvi.org), Mutation Taster (http://www.mutationtaster.org). Mutation
significance cut-off (MSC), a gene-level-specific cut-off for CADD scores, was generated for ALPI (http://pec630.rockefeller.edu:8080/MSC/).

monophosphorylated LPS retains only weak TLR4 agonist activity
(Schromm et al, 1998; Bates et al, 2007; Goldberg et al, 2008). As
the mutants identified here were all loss-of-function alleles, we
hypothesized that treatment of LPS with ALPI mutants would not
inhibit LPS immunostimulatory activity. Accordingly, and in
contrast with the WT allele, none of the ALPI mutants could significantly inhibit LPS-dependent IL-8 transcription in THP1 monocytic
cells (Fig 3G).
In vivo assessment of ALPI mutations
ALPI is mainly expressed in the small intestinal brush border, from
which it is released into the lumen within vesicles that transport
active ALPI towards distal intestinal sites (Eliakim et al, 1991;
Bates et al, 2007; Tuin et al, 2009; Shifrin et al, 2012; Malo,
2015). In keeping with in vitro evidence that ALPI mutations affect
protein expression, immunofluorescence analysis of small intestinal biopsies showed markedly reduced ALPI staining in P1 and P2
compared with histologically normal or IBD controls (Fig 4A and
B). In ALPI-deficient mice, alternative isoforms of alkaline phosphatase (AP) are upregulated (Narisawa et al, 2007). Similarly,
ALPI-deficient patients displayed enhanced expression of tissuenon-specific alkaline phosphatase (TNAP), the other AP isoenzyme
present in human gut mucosa (López-Posadas et al, 2011). In
contrast with ALPI, TNAP staining largely predominated in lamina
propria in controls and in ALPI-deficient patients. Yet, P1 and P2
also displayed some epithelial expression, suggesting that TNAP
might compensate for ALPI deficiency in the intestinal lumen
(Fig EV4). To address this question, AP activity was assessed in
stool in the presence of L-phenylalanine (L-Phe), a specific inhibitor of ALPI, or L-homoarginine (L-Arg), a specific inhibitor of
TNAP. As shown in Fig 4C, stools of non-inflamed controls
displayed substantial AP activity, which was largely inhibited by
L-Phe but not by L-Arg. This result was consistent with previous
reports indicating that most AP activity in stools is due to ALPI
with some residual AP activity of microbial origin (Malo, 2015;
Fig 4C). ALPI activity was significantly reduced in stools of
patients with intestinal inflammation (faecal calprotectin > 250 lg/

ª 2018 The Authors

g; Fig 4D), a result consistent with previous studies showing
decreased ALPI expression in the inflamed intestine (Molnár et al,
2012a,b). However, TNAP remained, as in controls, undetectable.
ALPI analysis could not be performed in P2, who refused stool
sampling, but both ALPI and TNAP were undetectable in P1 stools
sampled at time of remission 2 years after colectomy, confirming
the loss-of-function mutations in ALPI and the lack of intraluminal
substitution by TNAP in this patient.

Discussion
Herein, we report for the first time an inherited deficiency in ALPI
in two unrelated patients with severe intestinal inflammation refractory to medical treatment. Both patients carry compound heterozygous loss-of-function mutations that impair either stability or
catalytic activity of ALPI. Accordingly, ALPI expression is markedly
reduced in small intestinal biopsies, and its activity was undetectable in stools. ALPI is produced in the intestinal brush border
and released in an active form into the intestinal lumen where it can
dephosphorylate microbiota-derived LPS and thereby considerably
reduces its TLR4 agonist activity. In keeping with loss of function,
the mutated ALPI alleles could not inhibit LPS activity when
measured in vitro by the induction of IL-8 (Fig 3G). Although TNAP,
another AP expressed in the human gut mucosa, was upregulated in
the intestinal mucosa of both ALPI-deficient patients, we found no
evidence of its secretion in the intestinal lumen, a result consistent
with previous results (Malo, 2015). We therefore conclude that LPS
detoxification by ALPI in the intestinal lumen is severely impaired
in P1 and P2. This conclusion is in keeping with recent work showing how reduced expression of ALPI induced by recurrent non-lethal
Salmonella infections impairs intraluminal dephosphorylation/
detoxification of LPS (Yang et al, 2017). Since only two cases of
ALPI deficiency were identified, we suggest that this defect is instrumental in predisposing P1 and P2 to severe intestinal inflammation,
and our conclusions are strongly supported by data derived from
animal models (Malo et al, 2010; Ramasamy et al, 2011; Rentea
et al, 2012; Kaliannan et al, 2013; Fawley et al, 2017; Yang et al,
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Figure 3. Loss of function of ALPI mutants.
A, B Analysis with ALPI antibody of HEK293T cells (lacking endogenous ALPI expression) after mock transduction or transduction with lentiviral particles encoding
indicated mutants. (A) Western blot of whole-cell lysates. (B) Flow cytometry analysis of surface-labelled cells.
C–E 3D modelling of ALPI calculated on the basis of the crystal structure of ALPP. ALPI is represented with one monomer in yellow, and the second in blue. Alanine 350,
alanine 360 and catalytic Ser111 are represented in stick in violet, cyan and red, respectively. Deletion of the C-terminal from Gln439 is shown in pink. Top and
bottom views shown in (D) correspond to a 90° rotation.
F
pNPP phosphatase activity of WT and ALPI mutants measured by the OD405 nm of the reaction supernatants. n = 5, error bars indicate SD. **P = 0.0079,
nonparametric, unpaired two-tailed Mann–Whitney test.
G
IL-8 inhibition of LPS-induced transcription in THP1 cells by WT and ALPI mutants. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EV, empty vector. n = 3,
error bars indicate SD. **P = 0.022, nonparametric, unpaired two-tailed Mann–Whitney test.
Source data are available online for this figure.
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Figure 4. Reduced ALPI expression in patients’ small intestinal biopsies.
A, B Immunofluorescence microscopy of duodenum (A) and ileum (B) sections from Patient 1 (A) and Patient 2 (B) compared to normal or IBD controls. Sections were
stained with DAPI (40 ,6-diamidino-2-phenylindole) for DNA (blue) and antibodies against ALPI alone (second column, red) or ALPI and E-cadherin (green) (first
column, merge staining). Magnification 20× (scale bar = 100 lm).
C
Effect of AP inhibitors (L-phe, L-arg) on AP activity in stools of non-inflamed controls (n = 20). Data are expressed as mean  SD. ****P < 0.0001, nonparametric,
unpaired two-tailed Mann–Whitney test.
D
ALPI activity in stools of non-inflamed (n = 20) or IBD controls (n = 14) and of P1. AP values are expressed as units of ALPI/g stool and as medians with
interquartiles; *P = 0.0122, nonparametric, unpaired two-tailed Mann–Whitney test.
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2017). Zebrafish knocked down for ALPI displayed markedly
increased LPS-induced mortality upon oral challenge (Bates et al,
2007). Moreover, in the absence of ALPI, excessive numbers of
neutrophils were recruited into the intestine of conventionally raised
but not that of germ-free zebrafish, pointing to a key role for ALPI
in suppressing pro-inflammatory responses to the microbiota. In
mammals, there is ample evidence that continuous intestinal exposure to LPS induces the degradation of signalling molecules downstream of TLR4, so that, at steady state, epithelial cells and lamina
propria mononuclear phagocytes are largely unresponsive to LPS
(Smith et al, 2001; Lotz et al, 2006). Endogenous tolerance to LPS is
broken upon induction of inflammation induced either by gut injury
or infection, notably due to the recruitment of inflammatory
monocytes into the intestinal mucosa (Kamada et al, 2008). ALPImediated detoxification may then become indispensable to curb
inflammation. This scenario is coherent with data in ALPI-deficient
mice, which did not spontaneously develop intestinal inflammation,
but displayed markedly increased susceptibility to dextran sodium
sulphate-induced colitis (Ramasamy et al, 2011) as well as
increased gut permeability (Rentea et al, 2012) and enhanced LPS
translocation when subjected to direct or indirect gut injury
(Kaliannan et al, 2013). This scenario is also supported by data in
mice exposed to recurrent non-lethal infection by Salmonella typhimurium. The mice are able to eradicate the bacteria but ultimately
develop chronic colitis due to increased degradation of ALPI and
lesser availability of active ALPI in the intestinal lumen (Yang et al,
2017). The necessity of an environmental trigger to uncover genetic
susceptibility to intestinal inflammation in ALPI-deficient individuals might account for the distinct ages of P1 and P2 at disease onset,
leading to P1 developing very early onset IBDs while P2 presented
as a teenager. Of note, both patients developed autoantibodies and
diseases often linked to autoimmunity just before or concurrent to
distal intestinal inflammation. Thus, P1 developed coeliac disease,
to which he was genetically predisposed by the HLA-DQ2 haplotype,
while P2, who had an uncle with psoriatic arthritis, developed
arthritis. Whether ALPI deficiency favoured autoimmunity-related
manifestations in P1 and P2 remains uncertain. Indeed, the recent
suggestion that microbiota enriched in Bacteroidetes species producing hexa-acylated LPS with strong TLR4 agonist activity promotes
endotoxin tolerance and thereby protects against type I diabetes
(Vatanen et al, 2016) seems contradictory. Removal of one of the
two phosphorylated residues of LPS by ALPI may, however, be
necessary to fine-tune TLR4 activation and to foster endotoxin tolerance. Accordingly, injection of monophosphorylated lipid A could
attenuate LPS-induced inflammatory responses in healthy volunteers (Astiz et al, 1995).
Importantly, oral ALPI supplementation protected ALPI-deficient
mice from increased susceptibility to DSS-induced colitis (Ramasamy et al, 2011) and from chronic colitis induced by recurrent
non-lethal infections by S. typhimurium (Yang et al, 2017). This
treatment also significantly reduced intestinal inflammation in
several mouse models of colitis and prevented LPS translocation
(Ramasamy et al, 2011; Martı́nez-Moya et al, 2012; Rentea et al,
2012; Heinzerling et al, 2014; Biesterveld et al, 2015). Moreover, a
small trial in patients with ulcerative colitis showed that administration of exogenous ALPI was not only well tolerated but also associated with short-term improvement in clinical scores (Lukas et al,
2010). Altogether these data indicate that oral administration of
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recombinant ALPI is a very attractive therapeutic strategy in order
to alleviate intestinal inflammation in ALPI-deficient patients. At the
time of the present study, both P1 and P2 had undergone intestinal
resection and were in long-term remission, circumventing the need
for any further treatment. It is, however, tempting to speculate that
if oral ALPI supplementation had been initiated early after disease
onset, it might have prevented the development of refractory disease
and the need for surgery. These observations stress the importance
of early molecular diagnosis in patients with monogenic intestinal
disorders in order to optimize therapy and improve long-term
outcome and life quality.
In conclusion, our results support the view that ALPI deficiency is
a novel inherited cause of intestinal inflammation and underscore the
central and conserved role of ALPI in maintaining gut homeostasis.
Moreover, observations in patients with monogenic ALPI deficiency
provide strong rationale for oral ALPI treatment in common multifactorial cases of IBDs in order to alleviate ileocolonic inflammation.

Materials and Methods
Patients
For genetic studies, patients were enrolled in two independent IBD
paediatric cohorts in Hôpital Necker-Enfants Malades in Paris (P1)
and in Hospital for Sick Children in Toronto (P2). Genetic studies
were carried out in accordance with approved institutional protocols (CPP Ile-de-France II and the Research Ethics Board at the
Hospital for Sick Children) and conform to the 1975 Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. Informed consent for genetic testing was obtained
from all participants.
Dosage of ALPI activity was performed in the stools of 34
informed patients in parallel with calprotectin dosage performed
for diagnosis purposes in Pitié-Salpêtrière Hospital. They were
divided into two groups depending on calprotectin concentration:
inflamed (calprotectin > 250 lg/g; n = 14; aged 13–60 years) and
non-inflamed (calprotectin < 250 lg/g; n = 20; aged 2–66 years).
Whole-exome sequencing and analysis
Genomic DNA was isolated from peripheral blood cells with
QIAamp DNA Blood Mini Kit (Qiagen, Courtaboeuf, France; P1
family) and from whole blood with Puregene Blood Core Kit (Qiagen, Germantown, MD; P2 family). DNA was processed for exome
capture using the 58 Mb V6 version of the SureSelect Exome kit
(Agilent Technologies, Les Ulis, France; P1 and parents) or the
NimbleGen VCRome 2.1 design (Roche sequencing; P2 and
parents). Paired-end sequencing generating, respectively, 100- and
75-base reads was performed on Illumina HiSeq 2500 (Illumina, San
Diego, CA) at institute Imagine (P1) or at the Regeneron Genetics
Center (RGC; P2). Sequences were aligned with the GRCh37 reference human genome using the Burrows-Wheeler Aligner, and
downstream processing was carried out with the Genome Analysis
Toolkit (GATK), SAMtools and Picard, according to documented
best practices (http://www.broadinstitute.org/gatk/guide/topic?na
me=best-practices). Candidate variants were ranked by filtering out
common polymorphisms reported in public databases [Human Gene
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Mutation Database (HGMD), NHLBI GO Exome Sequencing Project
(ESP), 1000 Genomes Project, Exome Aggregation Consortium
(ExAc), database SNP (dbSNP)] or seen in the 10,681 exomes
sequenced at Institut Imagine from families affected with genetic
diseases. PolyPhen-2, SIFT and Mutation Taster were used to predict
consequences of mutations on protein function. Mutations were
next ranked on the basis of the predicted impact of each variant by
combined annotation-dependent depletion (CADD), and compared
with the mutation significance cut-off (MSC), a gene-level-specific
cut-off for CADD scores (Itan et al, 2016).
Sanger sequencing
ALPI variants identified by WES were confirmed by Sanger sequencing of PCR products amplified from genomic DNA. Primers used for
DNA amplification were as follows: A97T mutation: forward primer,
50 -GGACCTTCAGTGGTTCCAGG-30 and reverse primer, 50 -CCAAG
GACCTGGTTCTGGTC-30 ; A350V and A360V mutations: forward
primer, 50 -CGCGGCTTCTACCTCTTTGT-30 and reverse primer, 50 -GC
CTACCGAAGATGGAGCTC-30 , and Q439X mutation: forward primer,
50 -GAGCGGTGAGTGAGGCTGAA-30 and reverse primer, 50 -AGGTG
GGGAGCAGGATAACTC-30 . PCR was performed with AmpliTaq polymerase (Thermo Fisher Scientific, Villebon-sur-Yvette, France), using
a GeneAmp PCR system (9700; Applied Biosystems, Thermo Fisher
Scientific). PCR products were purified using QIAquick Gel Extraction Kit (Qiagen) and sequenced using the same primers by Eurofins
(the Genomic Platform of Université Paris Descartes, Paris, France).
Sequence analysis and molecular modelling of ALPI 3D structure
The 3D model of human ALPI was built from the crystal structure of
human placental alkaline phosphatase (entry code 1ew2; Le Du et al,
2001). Sequence homology between placental and intestinal alkaline
phosphatases was assessed by alignment using the Basic Local
Alignment Search Tool, BLAST (Altschul et al, 1997; Appendix Fig
S1). The full-atom model of ALPI was next calculated with the
program MODELLER (Sánchez & Sali, 2000). Conservation analysis
was then performed based on our 3D model of ALPI using the fully
automated evolutionary approach as implemented on ConSurf server
(Ashkenazy et al, 2016). Finally, visualization, analysis and figure
preparation of the 3D model were performed using PyMol software
(DeLano, W.L. The PyMOL Molecular Graphics System 2002).
Wild-type and mutant ALPI overexpression in HEK293T cells
For in vitro analysis of WT and mutant ALPI expression and activity,
a vector (pCR4-TOPO) containing the full cDNA sequence of human
ALPI transcript variant 1 (NM_001631.4; Dharmacon, Orsay, France)
was used. p.Ala97Thr (c.289G>A, GCT to ACT), p.Ala350Val
(c.1049C>T, GCG to GTG), p.Ala360Val (c.1079C>T, GCG to GTG),
p.Glu439X (c.1315C>T, CAG to TAG) mutations were introduced
using the GENEART Site-directed Mutagenesis System (Invitrogen,
Thermo Fisher Scientific) according to manufacturer’s instructions
for annealing, extension times and cycle numbers. Primer sequences
were as follows: 289_for 50 -CGCTTCCCATACCTGACTCTGTCCAA
GACAT-30 ;289_rev 50 -ATGTCTTGGACAGAGTCAGGTATGGGAAGC
G-30 ; 1049_for 50 -AGGCACTCACTGAGGTGGTCATGTTCGACGA-30 ,
1049_rev 50 -TCGTCGAACATGACCACCTCAGTGAGTGCCT-30 ;1079_
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for 50 -ACGCCATTGAGAGGGTGGGCCAGCTCACCAG-30 , 1079_rev
50 -CTGGTGAGCTGGCCCACCCTCTCAATGGCGT-30 ; 1315_for 50 -GGG
AGCCCCGATTACTAGCAGCAGGCGGCGG-30 ,1315_rev 50 -CCGCCGC
CTGCTGCTAGTAATCGGGGCTCCC-30 . Each construct was then
fully sequenced and subcloned into the pLenti-CMV-GFP-2A-Puro
plasmid (Applied Biological Materials, Richmond, CA). Lentiviral
particles encoding the different mutants were generated by transfecting HEK293T cells with transfer plasmid, packaging expressing plasmid psPAX2 (Addgene, Cambridge, USA), VSV-G envelope
expressing plasmid pMD2.G (Addgene) using Lipofectamine 2000
(Invitrogen, Thermo Fisher Scientific). Twelve hours after transfection, cells were washed, and fresh medium without antibiotics was
added for 60 h. The recombinant virus-containing medium was filtered and used to transduce HEK293T cells in the presence of polybrene (4 lg/ml). Positively transduced cells were selected with
puromycin (Gibco, Thermo Fisher Scientific) at 20 lg/ml concentration until all cells were GFP positive as assessed by FACS. Comparable transduction efficiency for WT and mutant constructs was
ascertained based on fluorescence of the GFP reporter.
Quantitative PCR
Total RNA was extracted from transduced-HEK293T cells using the
RNeasy Plus extraction kit (Qiagen). Total RNA (5 lg) was reverse
transcribed using M-MLV reverse transcriptase (Invitrogen). qRT–
PCR was performed with an Assays-on-Demand probe (Applied
Biosystems, Thermo Fisher Scientific) specific for ALPI-FAM
(Hs00357579_g1) and RPLPO-FAM (Large Ribosomal Protein;
Hs99999902_m1), which was used for normalization. qPCR was
performed with a ABI PRISM 7900 (Applied Biosystems). Results
are expressed according to the DDCt (cycle threshold) method.
Cell lysis, immunoblotting and flow cytometry
Total proteins were solubilized in RIPA buffer (Sigma, Saint
Quentin Fallavier, France) supplemented with 1× proteinase inhibitor cocktail mix (Roche, Sigma). Following separation by SDS–
PAGE, immunoblotting was performed using Ab against ALPI
(ab54776, 1 lg/ml, Abcam, Paris, France) and GAPDH (3683,
1:2,000, Cell Signaling). Surface cell staining of transduced cell
lines was performed according to standard flow cytometry protocol
using primary Ab against ALPI (ab54776, 1 lg/ml, Abcam), and
secondary BV510 goat anti-mouse (Poly4053, 1:100, Sony Biotechnologies, Weybridge, UK) was used. Data were analysed on FACS
Canto II (BD Biosciences, Rungis, France) using FlowJo software.
Alkaline phosphatase activity
Alkaline phosphatase activity was measured in cell lysates of
HEK293T cells expressing WT and mutant forms of ALPI by assessing p-nitrophenyl phosphate (pNPP) dephosphorylation using Alkaline Phosphatase Assay Kit (ab83369, Abcam) according to the
manufacturer’s instructions.
Alkaline phosphatase activity in stool
Stool samples were weighed, resuspended in assay buffer (ab83369,
Abcam) and homogenized in a FastPrep tube with six 2.5-mm glass
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Problem
Monogenic disorders associated with IBD-like intestinal inflammation
are a group of severe and rare conditions. Identifying the molecular
defect is necessary to optimize therapy and to improve long-term
outcome. It also provides insights into key mechanisms indispensable for establishing and maintaining intestinal homeostasis in
humans.
Results
Using whole-exome sequencing, we uncovered compound missense
mutations in intestinal phosphatase alkaline, ALPI, in two unrelated
patients. Severe colonic inflammation was associated with caeliac
disease in one HLA-DQ2+ child and with arthritis in the second
patient. ALPI is a brush border metalloenzyme that catalyses phosphate hydrolysis of the lipid moiety of LPS and thereby drastically
reduces LPS pro-inflammatory activity. Structural modelling and
heterologous expression of ALPI mutants in HEK293T cells showed
that all mutations were loss of function by impairing either stability
or catalytic activity of ALPI. Decreased ALPI expression on small
intestinal biopsies of both patients and lack of stool ALPI activity confirmed in vitro results.
Impact
This is the first time that loss-of-function mutations in ALPI are associated with monogenic forms of IBDs. Our results indicate that ALPI is
one conserved regulatory mechanism, which plays a key role to limit
inflammatory responses induced by microbiota-derived endotoxins.
ALPI mutations should be screened for in individuals with inflammatory bowel disease refractory to treatment. Early diagnosis of ALPI
deficiency should enable ALPI supplementation to prevent development of irreversible lesions and colectomy. ALPI supplementation
might also be useful to alleviate inflammation in polygenic IBD
patients, who usually display reduced ALPI expression.

beads installed (6913, MP Biomedicals, Illkirch, France) using the
FastPrep-24 Instrument (MP Biomedicals). Following centrifugation at 10,000 g for 10 min, the supernatant containing AP was
collected and assayed for AP concentration using Alkaline Phosphatase Assay Kit (ab83369, Abcam). Pre-treatment for 10 min with
L-phenylalanine (L-Phe, 10 mM; P2126, Sigma), a specific inhibitor
of ALPI or L-homoarginine (L-Arg, 10 mM; 101542, Sigma) a specific inhibitor of tissue-non-specific alkaline phosphatase (TNAP),
was used to determine the major isoform among stool APs. The
stool AP values are expressed as units of ALPI/g stool.
LPS dephosphorylation activity
To measure the LPS dephosphorylating activity of ALPI, HEK293T
cells expressing WT and mutant forms of ALPI were first incubated
with LPS 100 ng/ml. Supernatants were collected and used to stimulate the human monocytic cell line THP1. Total RNA was then
extracted from THP1 cells, and qRT–PCR was performed with an
Assays-on-Demand probe (Applied Biosystems) specific for IL8-FAM
(Hs00174103_m1) and RPLPO-FAM (Large Ribosomal Protein;
Hs99999902_m1), for normalization.
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Immunohistochemistry, antibodies and confocal microscopy
Formalin-fixed paraffin-embedded (FFPE) sections (5 lm) were cut
and dewaxed by heating at 60°C and xylene for 10 min three times
followed by different concentrations of ethanol to be rehydrated.
Afterwards one set of slides was stained with haematoxylin and
eosin for general views of histology. Antigen retrieval was
performed with high pressure cooking in ethylenediaminetetraacetic
acid (EDTA)-borate buffer [1 mM EDTA, 10 mM borax (sodium
tetraborate, Sigma-Aldrich Co., St Louis, USA), 10 mM boric acid
(Sigma-Aldrich Co.) with 0.001% Proclin 300 (Supelco, Bellefonte,
USA)] at pH 8.5. The slides were then blocked for 1 h at room
temperature with 4% BSA and 20% donkey serum in PBS, without
Ca2+ and Mg2+. Incubation with mixed primary antibodies, rabbit
polyclonal against ALPI Ab (PA5-22210, 1:200, Thermo Fisher,
Burlington, Canada), mouse monoclonal against TNAP Ab
(ab126820, 1:200, Abcam) and a goat polyclonal against E-cadherin
Ab (AF748, 1:400, R&D System, Minneapolis, USA) was performed
overnight at 4°C.
Slides were washed and incubated with donkey anti-rabbit
IgG H+L-rhodamine conjugate (705-095-147, Jackson ImmunoResearch Waltham, USA) and donkey anti-goat IgG H+L-FITC
conjugate (711-295-152, Jackson ImmunoResearch Waltham) for
2 h at room temperature in darkness. RedDot2 (1:200, Biotium,
Hayward, USA) was used at a dilution of 1:200 for nuclear
counter staining. These sections were mounted overnight with
Vectashield fluorescence mounting medium (Vector Labs, Burlingame, USA).
Fluorescent confocal images of normal, IBDs and mutant
duodenums or ileums for ALPI, TNAP and E-cadherin doublestained sections were obtained using a Leica confocal laser
scanning microscope (model TCS-SPE) and LAS-AF software
(Leica Microsystems Leica Microsystems, Wetzlar, Germany).
Image processing was carried out with Adobe Photoshop CS3
software. To visualize these images, some pseudocolour such as
far-red in blue was applied with the channel option of Photoshop CS3.
Statistical analysis
The statistical analysis was performed using GraphPad Prism
version 6.0. Data are presented as mean  standard deviation
unless specified otherwise. Nonparametric, unpaired two-tailed
Mann–Whitney test was used. Numbers of experiments and Pvalues are indicated in each figure legend.
Data availability
Whole-exome sequencing data have been deposited to the EGA
database (https://www.ebi.ac.uk/ega/) with the assigned identifier
EGAS00001002847 for patient P1 and EGAS00001003350† for
patient P2.
Expanded View for this article is available online.

Correction added on 14 January 2019, after first online publication: The accession code was corrected from EGAS00001002902 to EGAS00001003350.
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